Current status of third-line therapy for CML
Fabian Lang, MD, Goethe University, Frankfurt, Germany, comments on the tolerability and efficacy of asciminib in the treatment of patients with chronic myeloid leukemia (CML) in the third-line setting, highlighting the importance of improving the outcomes of this patient population and achieving a higher rate of treatment-free remission (TFR). This interview took place at the 24th Annual John Goldman Conference on Chronic Myeloid Leukemia (ESH CML) held in Mandelieu-La Napoule, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Watch video Current status of third-line therapy for CML online without registration, duration hours minute second in high quality. This video was added by user VJHemOnc – Video Journal of Hematology & HemOnc 24 October 2022, don't forget to share it with your friends and acquaintances, it has been viewed on our site 97 once and liked it 0 people.